Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug ...
Trodelvy dosing is 10 mg/kg IV on days 1 and 8 of 21-day cycles, continued until progression or unacceptable toxicity; pembrolizumab schedules follow prescriber determination. Safety requires ...
Pharmaceutical Technology on MSN
MSD’s Keytruda-Padcev combo secures EC approval for MIBC
The approval is based on results from the KEYNOTE-905/EV-303 trial, conducted in partnership with Pfizer and Astellas.
Merck & Co.’s first-in-class HIF-2 alpha inhibitor Welireg is touching down in the clear cell renal cell carcinoma (ccRCC) | ...
Cylembio combined with Keytruda improved progression-free survival in advanced melanoma, achieving 19.4 months versus 11.0 months with Keytruda alone. PD-L1 negative patients showed significant ...
This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and the first study in earlier-stage ...
Thursday, Merck & Co Inc (NYSE:MRK) provided updates on two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630. Merck is discontinuing the Phase 3 KEYNOTE-867 trial evaluating Keytruda (pembrolizumab) in ...
Add Yahoo as a preferred source to see more of our stories on Google. The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, New Jersey (Reuters) - Merck has stopped two ...
By Michael Erman June 22 (Reuters) - Pfizer said on Monday that one of the key experimental drugs it picked up in its $43 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results